The publication of positive trial results in a prestigious journal like the New England Journal of Medicine increases the credibility and visibility of Blueprint Medicines' avapritinib. This may lead to increased interest from healthcare providers and patients, potentially driving demand for the drug and positively impacting the company's stock price in the short term.